8 results about "Active immunity" patented technology

The invention provides a method for generating an active immune defense strategy under cloud-side cooperation, and the method comprises the steps: obtaining the state information of edge nodes in a cloud-side cooperation environment, carrying out the analysis of the node resource occupancy rate, network flow, and connection number key indexes, obtaining a node feature vector, and uploading the node feature vector to a cloud end; on the edge nodes, carrying out propagation speed evaluation and influence range analysis on potential malicious nodes, judging the diffusion trend of a high-risk threat, if the threat is in a rapid diffusion situation, executing complete isolation and network cut-off operations, and reporting the disposal situation to the cloud; in a cloud-side collaborative environment, recording historical behaviors and threat response conditions of each node, and identifying potential novel variant threats by calculating variant threat similarity; and updating the active immune rule base and the threat feature classification system of the cloud according to the result of the threat response and the newly discovered threat features by adopting a rule base dynamic updating mechanism, and synchronizing the updating to the edge node.

The invention discloses a manganese-based layered hydroxide modified by gold nanoparticles and a preparation method thereof, and relates to the technical field of drug synthesis, and the key points of the technical scheme are as follows: the layered morphology of Mn-LDH is observed on the manganese-based layered hydroxide in a transmission electron microscope, and spherical AuNPs dispersed on the surface and edge of a laminate have a uniform particle size and a uniform particle size. EDS energy spectrum analysis finds that gold, manganese, magnesium, aluminum and carbon elements exist, the hydrated particle size is 312 nm, and the dispersity is good. The material can initiate an excellent photo-thermal effect under the irradiation of 808nm near-infrared light to generate active oxygen and hydroxyl radicals to destroy bacterial cell walls and cell membranes, and the antibacterial effect can reach 99%. In addition, the material can stimulate a local active immune function, promote T cell infiltration and realize active immune sterilization. The nano material shows a remarkable anti-infection effect in an in-vitro antibacterial experiment and an in-vivo osteomyelitis animal model experiment, and a new insight is provided for treating osteomyelitis caused by methicillin-resistant staphylococcus aureus.

The application describes a phosphorylated tau targeted active Immunotherapy to treat preclinical Alzheimer's Disease.

The invention discloses a fermented ginseng-probiotic-natural antibacterial peptide composite oral liquid with an active immune defense function and a preparation method thereof, and belongs to the technical field of functional health food. The oral liquid is prepared by compounding a fermented ginseng matrix, an active probiotic preparation, a fly maggot source natural antibacterial peptide extract and auxiliary materials, and the activity of the components is guaranteed through a whole-course cold chain preparation process. On the basis of a microbial counterbalance theory, a human body active immune defense system is constructed by utilizing the synergistic effect of the fermented ginseng, the probiotics and the antibacterial peptide, and the limitation of traditional passive medical treatment is broken through; the shelf life of the product at 0-5 DEG C reaches 12 months, and the product is convenient to take and high in safety. The invention has the advantages of simple preparation process, wide raw material source and suitability for large-scale production, and has extremely high practical value in the field of human health protection.

The invention relates to the technical field of biological medicines, in particular to application of an METTL3 inhibitor in preparation of a medicine for enhancing antibacterial immunity of lungs. The m6A modification level of the AMs is regulated and controlled through an active immune enhancement scheme based on in-vivo pretreatment of an m6A inhibitor (STC-15), so that the ability of the AMs to swallow and remove bacteria is enhanced, and a brand-new host-oriented treatment thought is provided for resisting pulmonary infection.

The present invention provides a dynamic immune end-to-end trusted sharing method for multimodal data in a vehicle-road-cloud system, belonging to the field of information security technology. The method includes: using a vehicle-side or roadside unit with a digital certificate as the sending end, securely encapsulating the original multimodal data to generate a secure encapsulation result, and transmitting the secure encapsulation result to a cloud platform; using the cloud platform as the receiving end, recovering the original multimodal data; using the cloud platform to perform a trustworthiness assessment of the sending end based on the recovered original multimodal data (both current and historical), obtaining multi-dimensional assessment indicators; using a preset trust fusion model combined with the multi-dimensional assessment indicators to calculate and generate a dynamic trust value for the sending end; and triggering corresponding security handling strategies based on the dynamic trust value. This invention, through the synergistic linkage of dynamic trust value and security strategies, enables the system to possess adaptive perception and proactive immunity against internal threats, effectively ensuring the trustworthiness of shared data.

A method of treating a patient suffering from a cancer driven by a dysregulated human epidermal growth factor receptor (HER1 / human EGFR) comprising administering to a patient in need of such treatment a flexible proactive regimen to combine an anaplastic lymphoma kinase inhibitor (ALK inhibitor) with an anti-EGF antibody (mAb) for inhibiting the pathway activated by EGF-EGFR binding. The anti-EGF antibody can be produced by proactive immunization or provided passively by administration of an anti-EGF antibody. The method comprises administering the ALK inhibitor according to a continuous regimen based on an average daily dose ranging from 10 to 250 mg, and co-administering the mAb, either proactively or passively, according to a dosing regimen that achieves a therapeutically effective amount repeated three times a week, twice or once, once every two weeks, once every three weeks, or at least once a month.

The invention provides construction and application of an anti-IgLON5 antibody-related encephalopathy active immune animal model, and a construction method comprises the following steps: constructing a PKN-IgLON5 (1-313aa)-His (8 *) recombinant plasmid in vitro, and transfecting the plasmid into an HEK293S suspension cell to express protein; collecting cell supernate, purifying twice, and replacing a protein solvent with PBS (Phosphate Buffer Solution); an IgLON5 protein solution and a Freund's adjuvant are mixed to prepare an immune emulsion, the immune emulsion is subcutaneously injected into a mouse, the blood brain barrier is destroyed through pertussis toxin, a peripheral antibody is promoted to invade a central nervous system, and finally the active immune mouse model for resisting the IgLON5 antibody related encephalopathy is constructed. The invention discloses the construction method of the active immune animal model for the anti-IgLON5 antibody-related encephalopathy for the first time, the blank that no related research of the active immune model exists in the anti-IgLON5 antibody-related encephalopathy at present is filled, and the method is beneficial for reducing the full view of the antibody attacking the central nervous system and more comprehensively analyzing the phenotypes of cognition, sleep and dyskinesia.